Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms

作者：Scarpero Harriette^*; Sand Peter K; Kelleher Con J; Berriman Sandra; Bavendam Tamara; Carlsson Martin

来源：Current Medical Research and Opinion, 2011, 27(5): 921-930.

DOI：10.1185/03007995.2011.559581

• Efficacy
• Fesoterodine
• Health-related quality of life
• Overactive bladder
• Safety
• Tolerability

To evaluate long-term safety, tolerability, and efficacy of fesoterodine for men and women with overactive bladder (OAB) symptoms.
This was a post hoc analysis of data pooled from two open-label extensions (NCT00220402, NCT00220376) of double-blind studies. All subjects began open-label treatment with fesoterodine 8 mg once daily, with voluntary dose reduction to 4 mg and re-escalation to 8 mg each permitted once annually. Maximum allowable duration of open-label treatment ranged from 24 to 36 months.
Safety and discontinuations were assessed throughout treatment; subject-reported treatment tolerability and 3-day bladder diaries were evaluated at open-label baseline and months 1, 4, 8, 12, and 24.
A total of 185 men and 705 women enrolled; 83 men (45%%) and 356 women (50%%) continued open-label treatment for epsilon a parts per thousand yen24 months. Most men (84%%) and women (75%%) remained on fesoterodine 8 mg throughout open-label treatment. No new or unexpected safety signals were observed. Dry mouth was the most common treatment-emergent adverse event (men, 24%%; women, 32%%), rates of discontinuation due to dry mouth were low (men, 1%%; women, 2%%). Most men and women (epsilon a parts per thousand yen91%%) reported at least ''good'' tolerance. For men and women, statistically significant improvements in urgency urinary incontinence episodes, micturitions, urgency episodes, and mean voided volume per micturition achieved between double-blind baseline and open-label baseline were sustained or further improved through month 24; significant improvements in most OAB symptoms were observed between double-blind baseline and month 24 when subjects were stratified by double-blind treatment (placebo, tolterodine extended release 4 mg, fesoterodine 4 mg, fesoterodine 8 mg). Limitations include the lack of a placebo control and that subjects completing double-blind treatment may have been more likely to tolerate or respond to long-term fesoterodine treatment.
Long-term fesoterodine treatment was well tolerated and associated with sustained improvements in OAB symptoms in men and women.

• 出版日期2011-5